Miami, Florida 33136


Purpose:

In the present proposal the investigators wish to assess the effect of a single session with the device known as Exer-Rest® which applies Whole Body Periodic Acceleration (WBPA) on baseline airway blood flow (Qaw) and in Qaw variation, in current smokers, glucocorticoid-naïve asthmatics, and age-matched healthy never-smokers, with the expectation that the treatment will transiently increase the Qaw, and to a greater extent in the current smokers and patients with asthma who have endothelial dysfunction.


Study summary:

Endothelial shear stress activates nitric oxide synthase (NOS), leading to endothelium-dependent vasodilation. This can be accomplished through exercise or with a device known as Exer-Rest® which applies Whole Body Periodic Acceleration (WBPA) that is also called pGz. WBPA produces systemic vasodilation, by exerting shear stress on the vascular endothelium, activating endothelial NOS and releasing NO in animal models and human subjects. Cigarette smoking is associated with attenuated vascular relaxation responses in the systemic circulation. Patients with asthma also exhibit endothelial dysfunction in the airway. In this study the investigators wish to assess the effect of a single pGz session on baseline Qaw and delta Qaw in current smokers, glucocorticoid-naïve asthmatics, and age-matched healthy never-smokers to test if this treatment will increase the vascular relaxation responses.


Criteria:

Inclusion Criteria: 15 healthy never-smokers, 15 smokers (> than 1 year smoke history) and 15 never-smokers asmathics; FEV1 > 80% (except for asmathics subjets) Exclusion Criteria: Women of childbearing potential who do not accepted birth control measures; pregnant and breast feeding; cardiovascular disease or use of cardiovascular drugs; respiratory infection during the 4 weeks preceding the study; use of inhaled or systemic glucocorticoids, leukotriene modifiers or theophyllines in asmathics; FEV1 < 80% on the screening day (excepted for asmathics subjets)


NCT ID:

NCT01213706


Primary Contact:

Principal Investigator
Adam Wanner, MD
University of Miami

Adam Wanner, MD
Phone: (305) 243-2568
Email: awanner@miami.edu


Backup Contact:

Email: emendes@med.miami.edu
Eliana Mendes, MD
Phone: (305) 243-2568


Location Contact:

Miami, Florida 33136
United States

Adam Wanner, MD
Phone: 305-243-2568
Email: awanner@miami.edu

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: August 31, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.